Prognostic value of P-selectin and sST2 in patients with multiple myeloma

Cardiac involvement is one of the most important prognostic markers in multiple myeloma. However, value novel biomarkers, such as soluble suppression tumorigenicity 2 (sST2), P-selectin unknown The aim work was to investigate additive predictive effects biomarkers and sST2 for cardiovascular events myeloma patients. Materials methods. Levels were after anticancer treatment a total 67 median follow-up duration censored cases 14.0 (11.4–19.1) months. A 4 deaths occurred during period. ELISA method measurements circulating level used. Results. During follow-up, 36 unrelated recorded 18 (26.9 %) study, patients hospitalized 10 times due disease. At baseline with MM which appeared observation period had higher levels (P < 0.01), = 0,018), compared without events. Two showed satisfactory performances one-year from ROC analysis. Best cut-off values predicting selected (for – 31.05 ng/ml, sensitivity 71.5 % specificity 89.8 %; 54.21 69.6 86.2 %). combination better properties P-selectin. Conclusions. In confirmed myeloma, significant occurrence 1 year follow-up.